Results 21 to 30 of about 4,268 (199)

Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC)

Journal of the International AIDS Society, 2023
Introduction Data from two randomized controlled trials (RCTs) showed that injectable cabotegravir (CAB) for pre‐exposure prophylaxis (PrEP) was efficacious in reducing HIV acquisition.
Mitchell Warren, Wawira Nyagah, Catherine Verde Hashim, Michelle Rodolph, Robin Schaefer, Heather‐Marie A Schmidt, Rachel Baggaley   +6 more
doaj   +1 more source

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

, 2021
Combined antiretroviral treatments have significantly improved the morbidity and mortality related to HIV infection, thus transforming HIV infection into a chronic disease; however, the efficacy of antiretroviral treatments is highly dependent on the ...
Marzolini, C., Marzolini, C, Hodge, D, Back, DJ, Gibbons, S., Khoo, S.H., Khoo, SH, Back, D.J., Hodge, D., Gibbons, S   +9 more
core   +1 more source

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS DETERMINATION OF CABOTEGRAVIR AND RILPIVIRINE USING RP-HPLC [PDF]

Bulletin of Pharmaceutical Sciences. Assiut University
Type I HIV can be treated by the combination of these drugs. An accurate, precise, and novel RP-HPLC technique was developed and validated for concurrent assessment of cabotegravir and rilpivirine in bulk and medicinal formulation.
Sahitya Bharathi Chodimella, Raja Sundararajan   +1 more
doaj   +1 more source

Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long-Acting Intramuscular Injection in Real-World People with HIV. [PDF]

Long-acting cabotegravir has been studied mainly in the stringent framework of clinical trials, which does not necessarily reflect the situation of people with HIV (PWH) in routine clinical settings.
Decosterd, Laurent A., Stöckle, M., Guidi, M., Thoueille, Paul, Stöckle, Marcel, Furrer, H, Munting, Aline, Surial, Bernard, Ustero, Pilar, Saldanha, S.A., Schaller, F., Marzolini, C., Marzolini, C, Cavassini, M, Surial, B., Saldanha, SA, Thoueille, P., Calmy, Alexandra, Calmy, A, Girardin, François R., Schaller, Fabian, Günthard, Huldrych F., Di Benedetto, C., Schmid, Patrick, Buclin, T, Rauch, A, Duran Ramirez, J.J., Furrer, Hansjakob, Schaller, F, Marzolini, Catia, Schmid, P., Choong, E, Guidi, Monia, Günthard, HF, Di Benedetto, Caroline, Veuve, F, Ustero, P, Buclin, T., Duran Ramirez, JJ, Duran Ramirez, Jessy J, Munting, A., Ustero Alonso, Pilar, Buclin, Thierry, Di Benedetto, C, Bernasconi, E., Decosterd, Laurent A, Calmy, A., Günthard, Huldrych F, Ustero, P., Cavassini, M., Schmid, P, Braun, Dominique, Stöckle, M, Bernasconi, E, Braun, D., Rauch, A., Bernasconi, Enos, the Swiss HIV Cohort Study, Veuve, F., Decosterd, L.A., Munting, A, Girardin, François R, Rauch, Andri, Duran Ramirez, Jessy J., Furrer, H., Saldanha, Susana Alves, Choong, E., Veuve, François, Günthard, H.F., Girardin, FR, Guidi, M, Decosterd, LA, Choong, Eva, Girardin, F.R., Thoueille, P, Braun, D, Cavassini, Matthias, Surial, B   +77 more
core   +4 more sources

Long-Acting Injectable Antiretroviral Therapies for HIV Treatment and Prevention: Clinical Pharmacology, Recent Advances and Future Opportunities. [PDF]

J Clin Pharmacol
Abstract Long‐acting (LA) antiretroviral (ARV) medications represent a significant advancement in the HIV treatment and prevention field. LA ARVs help reduce daily pill burden and thus optimize adherence, which has translated into sustained virologic suppression in persons with HIV, prevention of HIV transmission among those at risk, and improved ...
Dunbar A, Rakhmanina N, Unternaher J, Anderson PL, Brooks KM.   +4 more
europepmc   +2 more sources

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF CABOTEGRAVIR & RILPIVIRINE BY RP HPLC METHOD

, 2022
A new method was established for simultaneous estimation of and cabotegravir and rilpivirine by RP-HPLC method. The Phosphate buffer was pH 3.2 and the mobile phase was optimized which consists of Acetonitrile: Phosphate buffer mixed in the ratio of 40 ...
Pindi Shravani, Dr. Nihar Ranjan Das
core   +1 more source

Clinical pharmacology considerations and drug-drug interactions with long-acting cabotegravir and rilpivirine relevant to sub-Saharan Africa. [PDF]

Long-acting injectable (LAI) cabotegravir and rilpivirine for HIV treatment and LAI cabotegravir for pre-exposure HIV prophylaxis are being rolled out in a multitude of countries worldwide.
Nicol, Melanie R, Obura, Bonniface, Waitt, Catriona, Laker, Eva, Steulet, Adrian, Cresswell, Fiona V   +5 more
core   +2 more sources

Formulation and Evaluation of Cabotegravir and Etravirine Tablets: A Factorial Study Incorporating Cyclodextrins and Tween 80 [PDF]

, 2022
The study aimed to investigate the formulation and evaluation of Cabotegravir and Etravirine tablets by incorporating cyclodextrins (β-CD and HPβ-CD) and Tween 80.
Dr. Govind Soni, Mrs. Shital Vijay Sirsat   +1 more
core   +1 more source

Formulation and pharmacology of long-acting cabotegravir [PDF]

Current Opinion in HIV and AIDS, 2015
Long-acting cabotegravir may provide a novel therapeutic option for both the treatment and prevention of HIV-1 infection that does not necessitate adherence to a daily regimen. The present review will highlight the unique formulation properties and pharmacologic attributes of long-acting cabotegravir nanosuspension.Cabotegravir is a potent integrase ...
Trezza, Christine, Ford, Susan L., Spreen, William, Pan, Rennan, Piscitelli, Stephen   +4 more
openaire   +2 more sources

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland

Pharmaceutics, 2022
SHCS#879 is an ongoing Switzerland-wide multicenter observational study conducted within the Swiss HIV Cohort Study (SHCS) for the prospective follow-up of people living with HIV (PLWH) receiving long-acting injectable cabotegravir-rilpivirine (LAI-CAB ...
Paul Thoueille, Susana Alves Saldanha, Fabian Schaller, Aline Munting, Matthias Cavassini, Dominique Braun, Huldrych F. Günthard, Katharina Kusejko, Bernard Surial, Hansjakob Furrer, Andri Rauch, Pilar Ustero, Alexandra Calmy, Marcel Stoeckle, Manuel Battegay, Catia Marzolini, Pascal Andre, Monia Guidi, Thierry Buclin, Laurent A. Decosterd, on behalf of the Swiss HIV Cohort Study   +20 more
doaj   +1 more source